Press Release: Ionis to hold first quarter 2025 financial results webcast

Dow Jones

04-16

Webcast scheduled for Wednesday, April 30 at 11:30 a.m. Eastern Time

CARLSBAD, Calif.--(BUSINESS WIRE)--April 16, 2025--

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 30(th) at 11:30 a.m. Eastern Time to discuss its first quarter 2025 financial results.

The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address.

About Ionis Pharmaceuticals, Inc.

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology, and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250416971161/en/

 
    CONTACT:    Ionis Pharmaceuticals Investor Contact:

D. Wade Walke, Ph.D. -- IR@ionis.com -- 760-603-2331

Ionis Pharmaceuticals Media Contact:

Hayley Soffer -- media@ionis.com -- 760-603-4679

(END) Dow Jones Newswires

April 16, 2025 07:08 ET (11:08 GMT)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2527294049"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2527294049\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2527294049?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-16 19:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2527294049","market":"sg","top_or_hot":-1,"title":"Press Release: Ionis to hold first quarter 2025 financial results webcast","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     Webcast scheduled for Wednesday, April 30 at 11:30 a.m. Eastern Time \n</p>\n<pre>\nCARLSBAD, Calif.--(BUSINESS WIRE)--April 16, 2025-- \n</pre>\n<p>\n     <a href=\"https://laohu8.com/S/IONS\">Ionis Pharmaceuticals, Inc</a>. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 30(th) at 11:30 a.m. Eastern Time to discuss its first quarter 2025 financial results. \n</p>\n<p>\n     The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. \n</p>\n<p>\n     About Ionis Pharmaceuticals, Inc. \n</p>\n<p>\n     For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology, and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram. \n</p>\n<p>\n     View source version on businesswire.com: https://www.businesswire.com/news/home/20250416971161/en/ \n</p>\n<pre>\n \n    CONTACT:    Ionis Pharmaceuticals Investor Contact: \n</pre>\n<p>\n     D. Wade Walke, Ph.D. -- IR@ionis.com -- 760-603-2331 \n</p>\n<p>\n     Ionis Pharmaceuticals Media Contact: \n</p>\n<p>\n     Hayley Soffer -- media@ionis.com -- 760-603-4679 \n</p>\n<pre>\n \n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 16, 2025 07:08 ET (11:08 GMT)\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Press Release: Ionis to hold first quarter 2025 financial results webcast</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPress Release: Ionis to hold first quarter 2025 financial results webcast\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-04-16 19:08</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     Webcast scheduled for Wednesday, April 30 at 11:30 a.m. Eastern Time \n</p>\n<pre>\nCARLSBAD, Calif.--(BUSINESS WIRE)--April 16, 2025-- \n</pre>\n<p>\n     <a href=\"https://laohu8.com/S/IONS\">Ionis Pharmaceuticals, Inc</a>. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 30(th) at 11:30 a.m. Eastern Time to discuss its first quarter 2025 financial results. \n</p>\n<p>\n     The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. \n</p>\n<p>\n     About Ionis Pharmaceuticals, Inc. \n</p>\n<p>\n     For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology, and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram. \n</p>\n<p>\n     View source version on businesswire.com: https://www.businesswire.com/news/home/20250416971161/en/ \n</p>\n<pre>\n \n    CONTACT:    Ionis Pharmaceuticals Investor Contact: \n</pre>\n<p>\n     D. Wade Walke, Ph.D. -- IR@ionis.com -- 760-603-2331 \n</p>\n<p>\n     Ionis Pharmaceuticals Media Contact: \n</p>\n<p>\n     Hayley Soffer -- media@ionis.com -- 760-603-4679 \n</p>\n<pre>\n \n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 16, 2025 07:08 ET (11:08 GMT)\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2527294049","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2527294049","pubTimestamp":1744801680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Webcast scheduled for Wednesday, April 30 at 11:30 a.m. Eastern Time. Ionis Pharmaceuticals, Inc.  announced today that it will host a live webcast on Wednesday, April 30 at 11:30 a.m. Eastern Time to discuss its first quarter 2025 financial results.For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology, and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X , LinkedIn and Instagram.D. Wade Walke, Ph.D. -- IR@ionis.com -- 760-603-2331","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IONS":"Ionis Pharmaceuticals, Inc"},"translate_title":"新闻稿：Ionis将举行2025年第一季度财务业绩网络广播","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IONS":0.9},"content_text":"Webcast scheduled for Wednesday, April 30 at 11:30 a.m. Eastern Time \n\n\nCARLSBAD, Calif.--(BUSINESS WIRE)--April 16, 2025-- \n\n\nIonis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, April 30(th) at 11:30 a.m. Eastern Time to discuss its first quarter 2025 financial results. \n\n\n     The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. \n\n\n     About Ionis Pharmaceuticals, Inc. \n\n\n     For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology, and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram. \n\n\n     View source version on businesswire.com: https://www.businesswire.com/news/home/20250416971161/en/ \n\n\n \n    CONTACT:    Ionis Pharmaceuticals Investor Contact: \n\n\n     D. Wade Walke, Ph.D. -- IR@ionis.com -- 760-603-2331 \n\n\n     Ionis Pharmaceuticals Media Contact: \n\n\n     Hayley Soffer -- media@ionis.com -- 760-603-4679 \n\n\n \n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 16, 2025 07:08 ET (11:08 GMT)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}